- Home
- REVB vs ALZN Comparison
REVB vs ALZN Comparison
Compare REVB & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- ALZN
- Stock Information
- Founded
- REVB 2020
- ALZN 2016
- Country
- REVB United States
- ALZN United States
- Employees
- REVB N/A
- ALZN N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- REVB Health Care
- ALZN Health Care
- Exchange
- REVB Nasdaq
- ALZN Nasdaq
- Market Cap
- REVB 5.4M
- ALZN 6.1M
- IPO Year
- REVB N/A
- ALZN 2021
- Fundamental
- Price
- REVB $0.40
- ALZN $1.16
- Analyst Decision
- REVB
- ALZN Strong Buy
- Analyst Count
- REVB 0
- ALZN 1
- Target Price
- REVB N/A
- ALZN $32.00
- AVG Volume (30 Days)
- REVB 6.8M
- ALZN 156.2K
- Earning Date
- REVB 11-08-2024
- ALZN 12-12-2024
- Dividend Yield
- REVB N/A
- ALZN N/A
- EPS Growth
- REVB N/A
- ALZN N/A
- EPS
- REVB N/A
- ALZN N/A
- Revenue
- REVB N/A
- ALZN N/A
- Revenue This Year
- REVB N/A
- ALZN N/A
- Revenue Next Year
- REVB N/A
- ALZN N/A
- P/E Ratio
- REVB N/A
- ALZN N/A
- Revenue Growth
- REVB N/A
- ALZN N/A
- 52 Week Low
- REVB $0.28
- ALZN $1.06
- 52 Week High
- REVB $25.26
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- REVB 39.87
- ALZN 44.56
- Support Level
- REVB $0.39
- ALZN $1.13
- Resistance Level
- REVB $0.53
- ALZN $1.26
- Average True Range (ATR)
- REVB 0.13
- ALZN 0.07
- MACD
- REVB 0.00
- ALZN 0.00
- Stochastic Oscillator
- REVB 7.54
- ALZN 32.37
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.